UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Hepatitis C virus infection in patients on maintenance dialysis

Authors
Marion Muche, MD
Seema Baid-Agrawal, MD
Section Editors
Steve J Schwab, MD
Martin S Hirsch, MD
Adrian M Di Bisceglie, MD
Deputy Editors
Alice M Sheridan, MD
Allyson Bloom, MD

INTRODUCTION

Hepatitis C virus (HCV) infection is common and associated with significant morbidity and mortality among dialysis patients.

This topic reviews HCV infection among dialysis patients, including epidemiology, screening, and prevention.

The treatment of HCV infection among patients with reduced renal function, including those on dialysis, is discussed elsewhere. (See "Treatment of chronic hepatitis C infection in adults with renal impairment", section on 'Severe renal impairment or dialysis'.)

General issues related to HCV infection among transplant kidney donors and recipients and recurrent or de novo HCV-related renal disease in transplant recipients are discussed elsewhere. (See "Hepatitis C virus infection in kidney donors" and "Hepatitis C infection in kidney transplant candidates and recipients".)

EPIDEMIOLOGY

HCV infection is more common in dialysis patients than in healthy populations. The Dialysis Outcomes and Practice Patterns Study (DOPPS) reported an overall prevalence of 13.5 percent among adult hemodialysis patients randomly selected from 308 dialysis facilities in developed countries (France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States) [1]. This is compared with a reported global prevalence of approximately 3 percent in the general population. (See "Epidemiology and transmission of hepatitis C virus infection", section on 'Global distribution'.)

               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: May 2017. | This topic last updated: May 15, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65:2335.
  2. Su Y, Norris JL, Zang C, et al. Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int 2013; 17:532.
  3. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52.
  4. de Jesus Rodrigues de Freitas M, Fecury AA, de Almeida MK, et al. Prevalence of hepatitis C virus infection and genotypes in patient with chronic kidney disease undergoing hemodialysis. J Med Virol 2013; 85:1741.
  5. Vidales-Braz BM, da Silva NM, Lobato R, et al. Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients. Virol J 2015; 12:8.
  6. Couroucé AM, Bouchardeau F, Chauveau P, et al. Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays). Nephrol Dial Transplant 1995; 10:234.
  7. Sauné K, Kamar N, Miédougé M, et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant 2011; 26:2309.
  8. Fabrizi F, Lunghi G, Raffaele L, et al. Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. Nephrol Dial Transplant 1997; 12:298.
  9. Biamino E, Caligaris F, Ferrero S, et al. [Prevalence of anti-HCV antibody positivity and seroconversion incidence in hemodialysis patients]. Minerva Urol Nefrol 1999; 51:53.
  10. Di Napoli A, Pezzotti P, Di Lallo D, et al. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006; 48:629.
  11. Amiri ZM, Shakib AJ, Toorchi M. Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. East Mediterr Health J 2005; 11:372.
  12. Assarehzadegan MA, Shakerinejad G, Noroozkohnejad R, et al. Prevalence of hepatitis C and B infection and HC V genotypes among hemodialysis patients in Khuzestan province, southwest Iran. Saudi J Kidney Dis Transpl 2009; 20:681.
  13. Othman B, Monem F. Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria. Infection 2001; 29:262.
  14. Aman K, Al-Dubai SA, Aman R, et al. Prevalence and associated factors of hepatitis C virus infection among renal disease patients on maintenance hemodialysis in three health centers in Aden, Yemen: a cross sectional study. Saudi J Kidney Dis Transpl 2015; 26:380.
  15. Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. Saudi J Kidney Dis Transpl 2010; 21:1165.
  16. Khodir SA, Alghateb M, Okasha KM, Shalaby Sel-S. Prevalence of HCV infections among hemodialysis patients in Al Gharbiyah Governorate, Egypt. Arab J Nephrol Transplant 2012; 5:145.
  17. Lioussfi Z, Errami Z, Radoui A, et al. Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors. Saudi J Kidney Dis Transpl 2014; 25:672.
  18. Covic A, Iancu L, Apetrei C, et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999; 14:40.
  19. Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006; 82:853.
  20. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO J 1998; 44:98.
  21. Geerlings W, Tufveson G, Ehrich JH, et al. Report on management of renal failure in Europe, XXIII. Nephrol Dial Transplant 1994; 9 Suppl 1:6.
  22. Valderrábano F, Jones EH, Mallick NP. Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995; 10 Suppl 5:1.
  23. Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004; 19:904.
  24. Baid-Agrawal S, Schindler R, Reinke P, et al. Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. J Hepatol 2014; 60:928.
  25. Espinosa M, Martn-Malo A, Ojeda R, et al. Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis 2004; 43:685.
  26. Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs 2015; 38:471.
  27. Khan S, Attaullah S, Ali I, et al. Rising burden of Hepatitis C Virus in hemodialysis patients. Virol J 2011; 8:438.
  28. Natov SN, Lau JY, Bouthot BA, et al. Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. New England Organ Bank Hepatitis C Study Group. Am J Kidney Dis 1998; 31:920.
  29. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51:981.
  30. Cendoroglo Neto M, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10:240.
  31. Weinstein T, Tur-Kaspa R, Chagnac A, et al. Hepatitis C infection in dialysis patients in Israel. Isr Med Assoc J 2001; 3:174.
  32. Pascual J, Teruel JL, Liaño F, Ortuño J. Home hemodialysis protects against hepatitis C virus transmission. Nephron 1993; 64:314.
  33. dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996; 11:2017.
  34. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993; 44:1322.
  35. Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001; 37:1004.
  36. Stuyver L, Claeys H, Wyseur A, et al. Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission. Kidney Int 1996; 49:889.
  37. Halfon P, Roubicek C, Gerolami V, et al. Use of phylogenetic analysis of hepatitis C virus (HCV) hypervariable region 1 sequences to trace an outbreak of HCV in an autodialysis unit. J Clin Microbiol 2002; 40:1541.
  38. Grethe S, Gemsa F, Monazahian M, et al. Molecular epidemiology of an outbreak of HCV in a hemodialysis unit: direct sequencing of HCV-HVR1 as an appropriate tool for phylogenetic analysis. J Med Virol 2000; 60:152.
  39. Olmer M, Bouchouareb D, Zandotti C, et al. Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection. Clin Nephrol 1997; 47:263.
  40. Sypsa V, Psichogiou M, Katsoulidou A, et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis 2005; 45:334.
  41. Bergman S, Accortt N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis 2005; 45:684.
  42. DuBois DB, Gretch D, dela Rosa C, et al. Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: gender-related differences in viral load. Am J Kidney Dis 1994; 24:795.
  43. Jeffers LJ, Perez GO, de Medina MD, et al. Hepatitis C infection in two urban hemodialysis units. Kidney Int 1990; 38:320.
  44. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327:1899.
  45. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50:1.
  46. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; :S1.
  47. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53:1022.
  48. Jadoul M, Fabrizi F. What are the management issues for hepatitis C in dialysis patients?: epidemiology and prevention of hepatitis C virus transmission in the hemodialysis setting. Semin Dial 2014; 27:449.
  49. Okuda K, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J Hepatol 1995; 23:28.
  50. Gilli P, Moretti M, Soffritti S, et al. Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients. Int J Artif Organs 1990; 13:737.
  51. Centers for Disease Control and Prevention (CDC). Hepatitis C virus transmission at an outpatient hemodialysis unit--New York, 2001-2008. MMWR Morb Mortal Wkly Rep 2009; 58:189.
  52. Alfurayh O, Sabeel A, Al Ahdal MN, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol 2000; 20:103.
  53. Niu MT, Alter MJ, Kristensen C, Margolis HS. Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody to hepatitis C virus. Am J Kidney Dis 1992; 19:345.
  54. Garcia-Valdescasas J, Bernal MC, Cerezo S, et al. Strategies to reduce the transmission of HCV infection in hemodialysis (HD) units (abstract). J Am Soc Nephrol 1993; 4:347.
  55. Castelnovo C, Sampietro M, De Vecchi A, et al. Diffusion of HCV through peritoneal membrane in HCV positive patients treated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1997; 12:978.
  56. Brugnano R, Francisci D, Quintaliani G, et al. Antibodies against hepatitis C virus in hemodialysis patients in the central Italian region of Umbria: evaluation of some risk factors. Nephron 1992; 61:263.
  57. Mitwalli A, al-Mohaya S, al Wakeel J, et al. Hepatitis C in chronic renal failure patients. Am J Nephrol 1992; 12:288.
  58. Rais-Jalali G, Khajehdehi P. Anti-HCV seropositivity among haemodialysis patients of Iranian origin. Nephrol Dial Transplant 1999; 14:2055.
  59. Vagelli G, Calabrese G, Guaschino R, Gonella M. Effect of HCV+ patients isolation on HCV infection incidence in a dialysis unit. Nephrol Dial Transplant 1992; 7:1070.
  60. Calabrese G, Vagelli G, Guaschino R, Gonella M. Transmission of anti-HCV within the household of haemodialysis patients. Lancet 1991; 338:1466.
  61. Taskapan H, Oymak O, Dogukan A, Utas C. Patient to patient transmission of hepatitis C virus in hemodialysis units. Clin Nephrol 2001; 55:477.
  62. Hubmann R, Zazgornik J, Gabriel C, et al. Hepatitis C virus--does it penetrate the haemodialysis membrane? PCR analysis of haemodialysis ultrafiltrate and whole blood. Nephrol Dial Transplant 1995; 10:541.
  63. Caramelo C, Navas S, Alberola ML, et al. Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid. Nephron 1994; 66:470.
  64. Noiri E, Nakao A, Oya A, et al. Hepatitis C virus in blood and dialysate in hemodialysis. Am J Kidney Dis 2001; 37:38.
  65. Lombardi M, Cerrai T, Dattolo P, et al. Is the dialysis membrane a safe barrier against HCV infection? Nephrol Dial Transplant 1995; 10:578.
  66. Froio N, Nicastri E, Comandini UV, et al. Contamination by hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis 2003; 42:546.
  67. Taal MW, van Zyl-Smit R. Hepatitis C virus infection in chronic haemodialysis patients--relationship to blood transfusions and dialyser re-use. S Afr Med J 2000; 90:621.
  68. El-Sherif A, Elbahrawy A, Aboelfotoh A, et al. High false-negative rate of anti-HCV among Egyptian patients on regular hemodialysis. Hemodial Int 2012; 16:420.
  69. Dzekova-Vidimliski P, Severova-Andreevska G, Trajceska L, et al. Aminotransferase activity as a poor predictor of liver disease progression in dialysis patients with chronic hepatitis C. Bratisl Lek Listy 2011; 112:568.
  70. Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94:3576.
  71. Wolf PL, Williams D, Coplon N, Coulson AS. Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis. Clin Chem 1972; 18:567.
  72. Fabrizi F, Martin P, Dixit V, et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis 1998; 31:647.
  73. Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008; 18:97.
  74. Barril G, Castillo I, Arenas MD, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 2008; 19:2288.
  75. Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection and kidney transplantation in 2014: what's new? Am J Transplant 2014; 14:2206.
  76. Liu CH, Liang CC, Huang KW, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol 2011; 6:1057.
  77. Kellner P, Anadol E, Hüneburg R, et al. The effect of hemodialysis on liver stiffness measurement: a single-center series. Eur J Gastroenterol Hepatol 2013; 25:368.
  78. Pawa S, Ehrinpreis M, Mutchnick M, et al. Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease. Clin Gastroenterol Hepatol 2007; 5:1316.
  79. Ahmad A, Hasan F, Abdeen S, et al. Transjugular liver biopsy in patients with end-stage renal disease. J Vasc Interv Radiol 2004; 15:257.
  80. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; :S1.
  81. Martin P, Carter D, Fabrizi F, et al. Histopathological features of hepatitis C in renal transplant candidates [see comment]. Transplantation 2000; 69:1479.
  82. Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22:1152.
  83. Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007; 14:697.
  84. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012; 19:601.
  85. Kiyosawa K, Sodeyama T, Tanaka E, et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991; 115:367.
  86. Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992; 16:1109.
  87. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997; 1:559.
  88. Lanphear BP, Linnemann CC Jr, Cannon CG, et al. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994; 15:745.
  89. Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control 1995; 23:273.